Targeting the EZH2-PPAR Axis Is a Potential Therapeutic Pathway for Pancreatic Cancer

Enhancer of zeste homolog 2 (EZH2) is abnormally highly expressed in pancreatic cancer (PC). However, it is not ideal to treat PC by inhibiting EZH2. This study reported that the combined use of pan-peroxisome proliferator-activated receptor (PPAR) agonist could significantly improve the anti-PC eff...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:PPAR Res
Main Authors: Hu, Jilong, Zheng, Zhinan, Lei, Jia, Cao, Yuxin, Li, Qiyun, Zheng, Zhi, Chen, Chuanjun
Formato: Artigo
Idioma:Inglês
Publicado em: Hindawi 2021
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8321753/
https://ncbi.nlm.nih.gov/pubmed/34335707
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2021/5589342
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados